Comparative Pharmacology
Head-to-head clinical analysis: GEOPEN versus LAROTID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GEOPEN versus LAROTID.
GEOPEN vs LAROTID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbenicillin is a bactericidal penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has activity against Gram-negative and some Gram-positive bacteria.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
2 g intravenously every 6 hours for susceptible infections.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
None Documented
None Documented
Terminal half-life 4-6 hours in normal renal function; prolonged to 10-20 hours in moderate renal impairment (CrCl 10-50 mL/min) and up to 30-50 hours in severe impairment (CrCl <10 mL/min).
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
Renal: 80-90% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <2%.
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic